Media ReleaseFrom: Boulos & Cooper Pharmaceuticals
First-in-class drug Ramizol® active against antibioticresistant C. difficle
A scientific paper published in the journal, Diagnostic Microbiology and Infectious Disease, has shown Ramizol®, a first-in-class stilbene-based investigational antibiotic for the treatment of CDI is effective against 100 clinical isolates of C. difficile. The paper, entitled 'Comparison of the in vitro Antibacterial Activity of Ramizol, Fidaxomicin, Vancomycin and Metronidazole Against 100 Clinical Isolates of Clostridium difficile by Broth Microdilution', has shown resistance emergence against vancomycin and metronidazole. The results have shown that vancomycin-resistant isolates are more than 250 times less susceptible (MIC > 8 μg/mL) to fidaxomicin compared to fidaxomin-sensitive strains (MIC90 = 0.03 μg/mL).
The research, which was undertaken jointly by Boulos & Cooper Pharmaceuticals, US-based Micromyx LLC and Flinders University, has shown there is no apparent impact of ribotype, toxin-production, or resistance to fidaxomicin, vancomycin or metronidazole on the activity of Ramizol.
Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said "C. difficile strains showing resistance to both vancomycin and fidaxomicin is an unexpected finding, given these two antibiotics have different mechanisms of action". Dr Boulos said. "The emergence of resistance against the only three antibiotics currently used for treating CDI is alarming, highlighting the need for novel, safe and effective antibiotics". He continued "We believe Ramizol has the potential to be the standard of care for treating CDI and has the potential to be a blockbuster drug".